
Safe transfer of prescribing guidance

TEWV Prescriber Summary – see Formulary



Successful Transfer of Prescribing – Key Points

Good communication is essential. Full guidance on what to include in the letter is provided on page 4 & 5 of this guidance. The aim of the letter should be to politely request that the GP takes over prescribing. The language should not be demanding and should reflect that there is an option not to take over prescribing. You should look to include everything that will give the GP the confidence that their prescribing will be safe and reflective of best practice. If the drug is included in easily accessible local or national guidelines, then the GP should be appropriately signposted. Always include a copy of shared care guidance if applicable. If prescribing is more complex, consider a direct phone call if appropriate or ask if the GP would accept transfer (once stabilised) before initiating.

Title	Safe Transfer of Prescribing Guidance				
Approved by	Drug & Therapeutics Committee	Drug & Therapeutics Committee Date of Approval 24 th March 2022 (minor 18/11/22)			
Protocol Number	PHARM-0023-V9.3				
	Page 1	l of 13			

Most medicines prescribed to treat mental health illnesses are covered by NICE guidance. Where prescribing follows NICE recommendations, it is expected that prescribing responsibilities can be transferred from secondary to primary care services once patients are stabilised on treatment. This allows secondary care services to concentrate on the provision of specialist support and increases access to services. It also offers a much more convenient system for patients obtaining their medicines and allows primary care to provide comprehensive management of all a patient's medication.

An underlying principle of this guidance is that prescribing, and monitoring responsibilities must be clearly defined to ensure safe transfer of prescribing. Advice is available from the <u>General Medical Council (GMC)</u> on shared care prescribing and NHS England; <u>Responsibilities for Prescribing between Primary and</u> <u>Secondary / Tertiary Care</u>

All the drugs in Chapter 4 of the BNF which are prescribed by the Trust have been classified into categories which determine their prescribing status.

Green Drugs	 Can be initiated and prescribed in all care settings Second line / alternative green drug
Amber: Specialist Initiation	• Specialist initiation. Can be initiated by a specialist and transferred to the GP once the patient is stabilised. In some cases, there may be a further restriction for use outlined - these will be defined in each case.
Amber: Shared Care	These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to the patients GP within written and agreed shared care protocols and according to the agreed process for transfer of care
Red Drugs	 Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
Not Approved	× Drugs that have been considered by the APC or other approved body (e.g. NICE, NTAG) and are not approved for prescribing (i.e. cannot be initiated, but can be continued if already established) within TEWV.
Not Reviewed	Drugs that haven't been reviewed by the APC yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in TEWV until such time that a decision is taken by the D&T & interface prescribing groups on their formulary status.

A full list of approved drugs is provided in Appendix 2 according to the classifications noted above.

Specialist Initiation includes TEWV prescribers working in primary care settings e.g. Community hubs, PCN practitioners, GP aligned services

The Formulary, with RAG list information, can be accessed online at <u>http://joint-formulary.tees.nhs.uk/</u>. Note that the formulary is described as the County Durham & Darlington formulary, but it is for the whole of TEWV.

Copies of guidance and shared care can be found on the TEWV website here.

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022 (minor 18/11/22)
Protocol Number	PHARM-0023-V9.3	Date of Review	1 st April 2024 (extended)

Contents

Transfer of prescribing procedure	4
Note: where the patient uses a monitored dosage system, extra care needs to be taken during t transfer process. A discussion is recommended to ensure the most appropriate route of supply made to maximise patient safety	' is
Suspension of primary care prescribing arrangements	4
Triggers for referral back to secondary care services or need for specialist advice	4
Access to services and specialist advice	5
Discharge of patients and quick referral back	5
Appendix 1: Discharge on psychotropic medication from in-patient units	6
Appendix 2: List of formulary status applicable for initiation by TEWV prescribers	7
4.1.1 Hypnotics	7
4.1.2 Anxiolytics	7
4.2.1 First generation antipsychotics	7
4.2.1 Second generation antipsychotics (oral)	7
4.2.2 Antipsychotic depots & long-acting injections	7
4.2.3 Antimanic drugs	8
4.3.1 Tricyclic and related antidepressants	8
4.3.2 Monoamine-oxidase inhibitors	9
4.3.3 Selective serotonin re-uptake inhibitors	9
4.3.4 Other antidepressants	9
4.4 CNS Stimulants & drugs used for ADHD	9
4.6 Drugs used in nausea and vertigo	9
4.8.2 Drugs used in status epilepticus	. 10
4.9.2 Antimuscarinic drugs use in Parkinsonism	. 10
4.10.1 Alcohol dependence	. 10
4.10.2 Nicotine dependence	. 10
4.10.3 Opioid dependence	. 10
4.11 Drugs for dementia	. 10
Appendix 3: Transfer of Prescribing Checklist	. 11
Appendix 4: Transfer of Prescribing Issues	. 12
Document changes:	. 13

Note local variations on the RAG status and equivalent TEWV RAG are stated below:

TEWV	NY & Y
Green	Green
Amber: Specialist Initiation	Amber
Amber: Shared Care	Amber (SCG)
Red	Red
Purple	Black
Grey	Grey

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022 (minor 18/11/22)
Protocol Number	PHARM-0023-V9.3	Date of Review	1 st April 2024 (extended)
		40	

Transfer of prescribing procedure

GREEN classified drugs should be transferred, notifying the GP via the regular clinic letter. Include details of diagnosis (ICD-10), drug, dose and frequency; formulation (especially if a modified release, liquid or non-oral preparation is required); clinical indications if first line option not prescribed or non-standard formulation prescribed and list any discontinued drugs. The letter should also note a clear plan regarding review and planned duration of treatment. As appropriate, 28 days treatment should be supplied to enable primary care to update their records and provide further prescriptions (if applicable).

Transfer of prescribing responsibility for amber specialist medication may be considered when:

- The patient's mental state has been stabilised*
- The patient's dosage has been stabilised* and treatment is approved for transfer of prescribing.
- Prescribing is within NICE recommendations.
- The stipulations related to specific drugs are met

AMBER: Specialist Initiation classified drugs should be transferred, as above. Note: added requirements for antipsychotics and antimanic medication.

Patients are regarded as stabilised on antipsychotics or antimanic medication, for the purpose of transfer of prescribing responsibility once they have completed their response to medication and there are no recognised problems with compliance or significant acute risks of harm to self or to others. They will usually have completed at least one month of treatment (or 3 months for antipsychotics - see appendix 1) and be suitable for 28-day prescriptions.

Drugs prescribed at doses above BNF limits, in combinations (except where the combination is for ADR control) or for unlicensed indications not recommended by NICE cannot be transferred using this standard process, but can be transferred in appropriate cases under individual agreement between specialist and GP. Communication in advance, including a phone call, to explain the rationale for treatment, may facilitate such transfer

AMBER: Shared Care classified drugs can only be transferred if the prescribing is in line with the parameters of the agreed shared care guideline. A copy of the applicable shared care guidance should be sent with the clinic letter. The GP must provide positive acceptance of the shared care request. All shared care guidelines can be found <u>here</u>.

RED, **PURPLE** and **GREY** drugs are not normally considered appropriate for transfer.

Note: where the patient uses a monitored dosage system, extra care needs to be taken during the transfer process. A discussion is recommended to ensure the most appropriate route of supply is made to maximise patient safety.

Suspension of primary care prescribing arrangements

Prescribing in primary care should be suspended and revert to secondary care when patients are being seen intensively by secondary care necessitating medication changes.

Where patients default from attending secondary care reviews, the risk/benefit of continued prescribing needs to be considered.

Triggers for referral back to secondary care services or need for specialist advice

These may include:

- Any spontaneous deterioration in mental state or increase in risk to self or others that cannot be managed by the GP
- Patient or carer request to review adverse side effects including the development of extra pyramidal side effects

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022 (minor 18/11/22)
Protocol Number	PHARM-0023-V9.3	Date of Review	1 st April 2024 (extended)

- Non-concordance or lack of efficacy
- Specific prescribing circumstances e.g. pregnancy, breast feeding, initiation of concomitant therapy that may interact with the patient's therapy or mental state
- Increase in smoking, alcohol or drug use
- Deterioration or abnormalities in monitoring results

Access to services and specialist advice

Contact details for rapid access to services and advice will be provided in the GP letter/shared care prescribing transfer request.

Discharge of patients and quick referral back

Discharge communication must clearly outline a medication treatment plan including expected length of treatment and criteria for review. Where this is not clear, the GP should request clarity.

For patients on **antipsychotic or antimanic medication**, consideration may be given to discharging patients from secondary care services where no active treatment is being provided by specialist services and the patient has:

- had at least one annual review by secondary care services and
- been stable on and concordant with treatment for a minimum of 6 months and
- is not receiving aftercare under Section 117 and
- there is no other co-morbidity requiring consultant psychiatrist input

This should only occur with:

- explicit agreement from the GP and
- a formalised written agreement between secondary care and primary care and
- after discussion with the patient.

It is advised that the discharge care planning arrangements specifically highlight requirements for on-going physical health monitoring.


For patients who may not require lifelong treatment; an indication of longer-term review arrangements, where discontinuation or review of treatment may be considered, should be specified.

If after discharge a patient becomes mentally unstable or a slow deterioration in mental health is observed a referral from primary care would result in prompt action by secondary care.

Patients that have been discharged can, within 3 months of discharge, be referred back directly to the discharging team.

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022 (minor 18/11/22)
Protocol Number	PHARM-0023-V9.3	Date of Review	1 st April 2024 (extended)

Appendix 1: Discharge on psychotropic medication from in-patient units



GREEN ●	GREEN O	AMBER: Specialist Initiation +	AMBER: Shared Care	RED !	PURPLE X or other
4.1.1 Hypnotics			<u> </u>		
Temazepam	Promethazine		Melatonin (Circadin) &	Melatonin (non-Circadin)	Melatonin (Colonis
Zopiclone	Zolpidem		liquid identified in Shared Care		Pharma brand)
 4.1.2 Anxiolytic: Initiation by special supply on transfer 		Anxiety Medication Pathway for Adults (or	nly if SSRIs or SNRIs not tole	erated); Stabilised on treatmen	t; Minimum of one mont
Diazepam	Lorazepam	Pregabalin			Meprobamate
		Buspirone			
				Zuclopenthixol acetate (injection)	Promazine
transferred when sta	abilised on treatment or p s whilst actively involved	Psychosis Care Pathway; Secondary car rescribed for 3 months (whichever is long	est); Minimum of one month's	s notice before transfer; Annua	I review of medication
		Benperidol		Zuclopenthixol acetate	Promazine
		Chlorpromazine			
		Haloperidol			
		Sulpiride			
		Trifluoperazine			
		Zuclopenthixol (oral)			
1.2.1. Cocord as					
Initiation by spec transferred when sta	eneration antipsych ialist; Prescribing follows abilised on treatment or p s whilst actively involved	otics (oral) Psychosis Care Pathway; Secondary car prescribed for 3 months (whichever is long in providing treatment Amisulpride	e will retain responsibility for est); Minimum of one month's	monitoring for 12 months; Press s notice before transfer; Annua Clozapine	I review of medication Paliperidone (oral)
Initiation by spec transferred when sta	ialist; Prescribing follows abilised on treatment or p	otics (oral) Psychosis Care Pathway; Secondary car prescribed for 3 months (whichever is long in providing treatment Amisulpride Aripiprazole	e will retain responsibility for est); Minimum of one month's	s notice before transfer; Annua	I review of medication Paliperidone (oral)
Initiation by spec ransferred when sta	ialist; Prescribing follows abilised on treatment or p	otics (oral) Psychosis Care Pathway; Secondary car prescribed for 3 months (whichever is long in providing treatment Amisulpride	e will retain responsibility for est); Minimum of one month's	s notice before transfer; Annua	I review of medication Paliperidone (oral) Lurasidone (all othe
Initiation by spec transferred when sta	ialist; Prescribing follows abilised on treatment or p	otics (oral) Psychosis Care Pathway; Secondary car prescribed for 3 months (whichever is long in providing treatment Amisulpride Aripiprazole	e will retain responsibility for est); Minimum of one month's	s notice before transfer; Annua	I review of medication Paliperidone (oral) Lurasidone (all othe
Initiation by spec transferred when sta	ialist; Prescribing follows abilised on treatment or p	otics (oral) Psychosis Care Pathway; Secondary car prescribed for 3 months (whichever is long in providing treatment Amisulpride Aripiprazole Lurasidone (Schizophrenia)	e will retain responsibility for est); Minimum of one month's	s notice before transfer; Annua	I review of medication Paliperidone (oral) Lurasidone (all other

Appendix 2: List of formulary status applicable for initiation by TEWV prescribers

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)
	Dece 7	£ 4 2	

GREEN ●	GREEN O	AMBER: Specialist Initiation +	AMBER: Shared Care	RED !	PURPLE X or othe
NOTE: If the trans	sfer of care was made prior	to 11/7/2019 then these drugs were cons	idered as "amber specialist ir	nitiation" (except paliperidone	and aripiprazole which
	n amber shared care) and tr ransfer from 11/7/2019 onw	nerefore patients' do not need to be referm ards.	ed back by primary care to es	stablish shared care. A share	ed care agreement is
, ,					_
			Aripiprazole	Olanzapine	
			Flupentixol Decanoate		
			Haloperidol Decanoate		
			Paliperidone		
			Risperidone		
			Zuclopenthixol Decanoate		
ntipsychotics: So onths (whicheve eatment	econdary care will retain res er is longest); Minimum of o	Bipolar Disorder Medication Pathway; sponsibility for monitoring for 12 months; F ne month's notice before transfer; Annual	Prescribing can be transferred I review of medication by spec	d when stabilised on treatme cialist services whilst actively	nt or prescribed for 3 involved in providing
ntipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	sponsibility for monitoring for 12 months; F ne month's notice before transfer; Annual protocol when transferring prescribing	Prescribing can be transferred review of medication by spec Lithium Carbonate	d when stabilised on treatme cialist services whilst actively	involved in providing
ntipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	sponsibility for monitoring for 12 months; F ne month's notice before transfer; Annual	l review of medication by spec	d when stabilised on treatme cialist services whilst actively	nt or prescribed for 3 involved in providing Asenapine
ntipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	ponsibility for monitoring for 12 months; F ne month's notice before transfer; Annual protocol when transferring prescribing Olanzapine	I review of medication by spec	d when stabilised on treatme cialist services whilst actively	involved in providing
ntipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	sponsibility for monitoring for 12 months; F ne month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine	Lithium Carbonate	d when stabilised on treatme cialist services whilst actively	involved in providing
ntipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	protocol when transferring prescribing Olanzapine Risperidone Olanzapine Risperidone	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of	d when stabilised on treatmen cialist services whilst actively	involved in providing
ntipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	protocol when transferring prescribing Olanzapine Quetiapine Carbamazepine	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential:	d when stabilised on treatme cialist services whilst actively	involved in providing
Antipsychotics: Se nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	 sponsibility for monitoring for 12 months; Fine month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine Risperidone Carbamazepine Lamotrigine 	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential: Sodium valproate	d when stabilised on treatmen cialist services whilst actively	involved in providing
Antipsychotics: So nonths (whicheve reatment	econdary care will retain res er is longest); Minimum of o	 sponsibility for monitoring for 12 months; Fine month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine Risperidone Carbamazepine Lamotrigine Sodium valproate Valproic acid Aripirazole 	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential:	d when stabilised on treatme cialist services whilst actively	involved in providing
Antipsychotics: Se nonths (whicheve reatment _ithium & Valproa	econdary care will retain res er is longest); Minimum of o ate	 sponsibility for monitoring for 12 months; Fine month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine Risperidone Carbamazepine Lamotrigine Sodium valproate Valproic acid Aripirazole Haloperidol 	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential: Sodium valproate	d when stabilised on treatme cialist services whilst actively	involved in providing
Antipsychotics: Se nonths (whicheve reatment _ithium & Valproa	econdary care will retain res er is longest); Minimum of o	sponsibility for monitoring for 12 months; Fine month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine Risperidone Carbamazepine Lamotrigine Sodium valproate Valproic acid Aripirazole Haloperidol essants	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential: Sodium valproate	d when stabilised on treatmen cialist services whilst actively	involved in providing
Antipsychotics: Se nonths (whicheve reatment <u>ithium & Valproa</u> 4.3.1 Tricyclic Prescribing follow	econdary care will retain res er is longest); Minimum of o ate	sponsibility for monitoring for 12 months; Fine month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine Risperidone Carbamazepine Lamotrigine Sodium valproate Valproic acid Aripirazole Haloperidol essants	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential: Sodium valproate	d when stabilised on treatment cialist services whilst actively	involved in providing
Antipsychotics: Se months (whicheve reatment _ithium & Valproa	econdary care will retain res er is longest); Minimum of o ate Follow shared care Follow shared care and related antideprove S Depression Medication Pa	sponsibility for monitoring for 12 months; Fine month's notice before transfer; Annual protocol when transferring prescribing Olanzapine Quetiapine Risperidone Carbamazepine Lamotrigine Sodium valproate Valproic acid Aripirazole Haloperidol essants	Lithium Carbonate (Priadel) Lithium Citrate (specify brand name) In girls and women of child bearing potential: Sodium valproate	d when stabilised on treatmen cialist services whilst actively	involved in providing Asenapine

Title	Safe Transfer of Prescribing Guidance)	
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)

Nortriptyline

	GREEN O	AMBER: Specialist Initiation +	AMBER: Shared Care	RED !	PURPLE X or othe
	ne-oxidase inhibitors	-	<u> </u>		
		Depression Medication Pathway for Adul	ts & Anxiety Medication Pathy	vay for Adults; Stabilised o	n treatment; Minimum of
ne month's supply	on transfer				
		Moclobemide			Tranylcypromine
		Phenelzine			Isocarboxazid
	serotonin re-uptake				
		Depression Medication Pathway for Adul		ay for Adults & Depression	Pathway CYP - guidance
<u>1 pnarmacological</u>	<u>management</u> ; Stabilised	on treatment; Minimum of one month's su	apply on transfer		
italopram					Paroxetine
scitalopram					Fluvoxamine
luoxetine					(only used for existing patients and patients
					moving into the area
ertraline					
Sertraline					already stabilised on
.3.4 Other anti		a Depression Mediaetian Dethugu for Ad	ute & Anviety Medicetion Det	wey for Adulto, Stebiliood	already stabilised on paroxetine or fluvoxamine)
	ecialist; Prescribing follow	s <u>Depression Medication Pathway for Adu</u> Venlafaxine > 225mq	ults & Anxiety Medication Path	-	already stabilised on paroxetine or fluvoxamine)
. 3.4 Other anti Initiation by a spe	ecialist; Prescribing follow on transfer;	s <u>Depression Medication Pathway for Adu</u> Venlafaxine > 225mg Reboxetine	ults & Anxiety Medication Path	nway for Adults; Stabilised Agomelatine Bupropion	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spending the month's supply Iirtazapine Cenlafaxine .4 CNS Stimul	ecialist; Prescribing follow on transfer; Vortioxetine	Venlafaxine > 225mg Reboxetine for ADHD	ults & Anxiety Medication Path	Agomelatine	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spene month's supply lirtazapine enlafaxine .4 CNS Stimul	ecialist; Prescribing follows on transfer; Vortioxetine Duloxetine ants & drugs used for	Venlafaxine > 225mg Reboxetine for ADHD	Atomoxetine	Agomelatine	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spenne ne month's supply Iirtazapine Yenlafaxine .4 CNS Stimul	ecialist; Prescribing follows on transfer; Vortioxetine Duloxetine ants & drugs used for	Venlafaxine > 225mg Reboxetine for ADHD	Atomoxetine Dexamfetamine	Agomelatine	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spenne ne month's supply Iirtazapine Yenlafaxine .4 CNS Stimul	ecialist; Prescribing follows on transfer; Vortioxetine Duloxetine ants & drugs used for	Venlafaxine > 225mg Reboxetine for ADHD	Atomoxetine Dexamfetamine Guanfacine	Agomelatine	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spenne ne month's supply Iirtazapine Yenlafaxine .4 CNS Stimul	ecialist; Prescribing follows on transfer; Vortioxetine Duloxetine ants & drugs used for	Venlafaxine > 225mg Reboxetine for ADHD	Atomoxetine Dexamfetamine Guanfacine Lisdexamfetamine	Agomelatine	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spe ne month's supply lirtazapine enlafaxine .4 CNS Stimul	ecialist; Prescribing follows on transfer; Vortioxetine Duloxetine ants & drugs used for	Venlafaxine > 225mg Reboxetine for ADHD	Atomoxetine Dexamfetamine Guanfacine	Agomelatine	already stabilised on paroxetine or fluvoxamine)
.3.4 Other anti Initiation by a spenne month's supply /irtazapine /enlafaxine .4 CNS Stimul . Follow shared c	Vortioxetine Duloxetin	Venlafaxine > 225mg Reboxetine For ADHD erring prescribing	Atomoxetine Dexamfetamine Guanfacine Lisdexamfetamine	Agomelatine	already stabilised on paroxetine or fluvoxamine)

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)

	GREEN O	AMBER: Specialist Initiation +	AMBER: Shared Care	RED !	PURPLE X or other
4 8 2 Drugs use	d in status epileptic		#		
Diazepam	Lorazepam				
Midazolam					
	rinic drugs use in F	Parkinsonism			
4.5.2 AntimuScu	inite drugs use in r	Procyclidine			
		Orphenadrine			
		Trihexyphenidyl			
4.10.1 Alcohol de	nendence	тнюхурненку			
		nmissioned service; Prescribing follows <u>N</u>	IICE CG115 alcohol depende	ence and harmful alcohol use:	
				Acamprosate	
				Chlordiazepoxide	
				Disulfiram	
				Nalmefene	
				Naltrexone	
4.10.2 Nicotine de	ependence				
		<mark>guidelines</mark> and does not reflect primary ca	re / local authority commissio	oning arrangements.	
Nicotine (NRT)					
4.10.3 Opioid dep					
Initiation and cont	inuation by specialist cor	nmissioned service			
				Buprenorphine	
				Lofexidine	
				Methadone	
				Naltrexone	
				Suboxone	
4.11 Drugs for de		(see guidance); Prescribing follows Dem	entia Care Pathway		
		Donepezil			
		Galantamine			
		Memantine			

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)

Appendix 3: Transfer of Prescribing Checklist

BEFORE TRYING TO TRANSFER PRESCRIBING: CHECKING IT'S APPROPRIATE

- □ I have reviewed the formulary status of the medication and it is appropriate to transfer
- The medication and patient's mental health is stable (i.e the patient has completed their response to medication and there are no recognised problems with compliance or significant acute risks of harm to self or to others).
- There has been consideration of STOMP (if applicable)
- The patient has completed at least one month of treatment (or 3 months for antipsychotics) and is suitable for 28 day prescriptions
- A minimum of one month's notice has been provided to the GP to ensure adequate time to add the prescription to the GP system

AMBER SHARED CARE: FOLLOWING THE SHARED CARE PROTOCOL

- There is a shared care protocol available to use (NOTE: if there isn't one available, then it the medication is not shared care and shouldn't be referred to as such)
- □ The patient & medication meets all of the criteria defined within the shared care protocol
- A clear letter has been written to the GP and a copy of the shared care protocol has been sent
- Arrangements have been made to continue prescribing until the GP agrees to shared care being established for this patient
- Arrangements have been made for the necessary secondary care responsibilities to be carried out (as defined in the protocol)

UNLICENSED / OFF-LABEL MEDICATION: ASK FIRST

- The medication has been supported for prescribing in TEWV (is on pre-approved list or has had an application approved)
- The patient has been informed of the licensing status of the drug
- L It is reasonable to ask a non-specialist to takeover prescribing with appropriate secondary care input
- □ The transfer has been discussed by phone or letter with the GP and they have agreed to the transfer
- A clinic letter has been sent which provides the GP with an appropriate management plan to support prescribing

DISCHARGE FROM SECONDARY CARE SERVICES ON ANTIPSYCHOTICS OR ANTIMANIC MEDICATION: WHAT NEEDS TO BE CONSIDERED

- The medication is NOT amber shared care, red or purple
- □ No active treatment is being provided by TEWV specialist services
- $\hfill\square$ There has been at least one annual review, by secondary care
- □ The patient has been stable on, and concordant with, treatment for a minimum of 6 months
- □ The patient is not receiving section 117 after care
- Discharge communication clearly outline a medication treatment plan including expected length of treatment and criteria for review

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)

Appendix 4: Transfer of Prescribing Issues

WHAT TO DO IF THE GP HAS QUERIED OR NOT ACCEPTED THE TRANSFER REQUEST:

SELF CHECK

- Have you followed all of the guidance within this document?
- □ Can you provide any supporting information to enable a successful transfer?
- □ Would a phone call to the GP help?
- □ Is it reasonable for the GP not to accept this transfer?

PEER SUPPORT

- Discuss the case with someone in your team. Can they provide any additional guidance? (NOTE: Ensure it's a peer that understands this document)
- Ask a colleague to review your transfer request letter and provide any helpful suggestions
- Consider trying again (best with a phone call) if the peer support has provided some different insight

LOCALITY SUPPORT

- □ Is this a persistent problem in a locality, or with a GP practice or an individual GP?
- □ Is the request definitely within the boundaries of this guidance?
- Discuss in an appropriate forum and seek advice
- Escalate to specialty governance group if there is a theme

PHARMACY SUPPORT

- □ If there is a pattern / theme were transfer is not being accepted, but is considered acceptable according to this guidance then consider discussion / email with <u>Christopher.williams@nhs.net</u> or <u>Richard.morris2@nhs.net</u>
- Pharmacy may not be able to resolve the specific issue, but it can help to shape future guidance and raise concerns through the Area Prescribing Committee

Title	Safe Transfer of Prescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)

Document changes:

August 2023	V9.3	Review date extended to 1 st April 2024
November	V9.3	Minor change – page 12. Removed GP advisor (role no longer available) and amended QuAG
2022		to governance group
February	V9.2	Updated wording throughout to specific better between secondary care, primary care, GP and
2022		specialist (recognising embedded mental health specialist practitioners). Definition to include
		this added to page 2.
		Removed reference on page 2 to quick reference guides (which no longer exist).
		All hyperlinks updated.
July 2020	V9.1	Lurasidone now amber SI for licensed indication & duloxetine is green.
July 2020		Minor amendments / clarity in green drugs box on page 1
May 2020	V9.0	RAG formulary status amended to match new APC format (green+ now amber specialist initiation/recommendation). Green and amber specialist initiation box separated in narrative.
		Additional comment added re: MDS.
		Appendix 1 added – guide to discharge from inpatients on psychotropic medication
		Appendix 2: Drug lists updated throughout to match formulary: Hyperlinks added and updated.
		Colour added to table to define differences.
		4.1.1 – melatonin (colonis pharma) added as purple
		4.1.2 – chlordiazepoxide deleted. Meprobamate added as purple.
		4.2.1 – promazine added as purple
		4.2.2 – all depots / LAIs (except olanzapine) now amber shared care
		4.3.1 – added nortriptyline as green. Dosulepin and trimipramine added as purple.
		4.3.2 – tranylcypromine and isocarboxazid added as purple
		4.3.3 – fluvoxamine removed. Paroxetine added as purple.
		4.3.4 – reboxetine moved from green to amber specialist initiation
		Section 4.8.1 (antiepileptics) removed as TEWV prescribers will not normally initiate
		4.8.2 – clonazepam, phenobarbital and phenytoin removed Appendix 3: new checklist added
		Appendix 3: new checklist added Appendix 4: new checklist for transfer of prescribing challenges
21 st June	V8.1	Hyperlinks corrected throughout. Formulary hyperlink added to first page.
2019	10.1	Typoliniko conceted tiloughedt. Tonnalary Typolinik added to met page.
19 th June	V8	Guanfacine moved to amber (was red). TEWV prescriber summary added to page 1.
2018		Fluphenazine decanoate removed as being discontinued. Page 3: shared care requires
		acceptance and comment added for combinations for ADR control. Hyperlinks amended and
		added throughout. Additional supportive text & signposting added throughout. Drugs for
		dementia amended in line with NICE.
2 nd June	V7.1	Lisdexamfetamine now amber (was red) and clarification added re: antipsychotics on page 3.
2017		Hyperlinks to website updated.

Title	Safe Transfer of Prescribing Guidance				
Approved by	Drug & Therapeutics Committee	Date of Approval	24 th March 2022		
Protocol Number	PHARM-0023-V9.2	Date of Review	1 st April 2024 (extended)		